CD14 and lipopolysaccharide binding protein expression in a rat model of alcoholic liver disease

G L Su, A Rahemtulla, P Thomas, R D Klein, S C Wang, A A Nanji, G L Su, A Rahemtulla, P Thomas, R D Klein, S C Wang, A A Nanji

Abstract

Lipopolysaccharide-binding protein (LBP) and CD14 play key intermediary roles in the activation of cells by endotoxin. As endotoxin has been postulated to participate in promoting pathological liver injury in alcoholic liver disease, we investigated the role of LBP and CD14 in alcoholic liver injury. Rats were fed intragastrically ethanol or dextrose and either medium-chain triglycerides, corn oil, or fish oil for 4 weeks. Kupffer cells, endothelial cells, and hepatocytes were isolated. LBP and CD14 mRNA levels were measured in liver and individual cell types. The highest levels of LBP and CD14 mRNA levels in the liver were found in the fish oil/ethanol group, which was also the group with the greatest degree of pathological injury and inflammation. CD14 mRNA levels were also significantly elevated in groups fed unsaturated fatty acids with dextrose. CD14 expression was localized to the Kupffer cells and LBP expression to the hepatocytes. Expression of CD14 mRNA was also found in nonmyeloid cells in the two experimental groups (fish oil/ethanol and corn oil/ethanol) that had liver necrosis and inflammation. Our results suggest that enhanced LBP and CD14 expression correlates with the presence of pathological liver injury in alcoholic liver injury. Furthermore, unsaturated fatty acids may prime cells to respond to endotoxin by enhancing CD14 expression.

References

    1. Alcohol Clin Exp Res. 1986;10(6 Suppl):13S-19S
    1. Hepatology. 1986 Sep-Oct;6(5):814-22
    1. Annu Rev Med. 1987;38:417-32
    1. Anal Biochem. 1987 Apr;162(1):156-9
    1. Life Sci. 1989;44(3):223-7
    1. Alcohol Clin Exp Res. 1989 Feb;13(1):15-9
    1. Pathobiology. 1990;58(2):89-94
    1. Science. 1990 Sep 21;249(4975):1429-31
    1. Science. 1990 Sep 21;249(4975):1431-3
    1. Am J Physiol. 1990 Dec;259(6 Pt 1):G907-12
    1. Science. 1991 May 31;252(5010):1321-2
    1. J Exp Med. 1992 Jun 1;175(6):1697-705
    1. Arch Surg. 1993 Jan;128(1):22-7; discussion 27-8
    1. Am J Pathol. 1993 Feb;142(2):367-73
    1. J Immunol. 1993 Apr 1;150(7):2885-91
    1. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2380-4
    1. Semin Liver Dis. 1993 May;13(2):170-82
    1. J Exp Med. 1994 Jan 1;179(1):269-77
    1. Clin Exp Metastasis. 1994 Mar;12(2):108-16
    1. J Exp Med. 1994 May 1;179(5):1671-6
    1. Proc Soc Exp Biol Med. 1994 Mar;205(3):243-7
    1. Hepatology. 1994 Jun;19(6):1483-7
    1. J Immunol. 1994 Jun 15;152(12):5868-76
    1. J Pharmacol Exp Ther. 1994 Jun;269(3):1280-5
    1. J Immunol. 1994 Jul 15;153(2):743-52
    1. J Leukoc Biol. 1994 Jul;56(1):1-9
    1. Hepatology. 1994 Aug;20(2):453-60
    1. Hepatology. 1994 Aug;20(2):461-74
    1. Life Sci. 1994;55(8):611-20
    1. J Exp Med. 1994 Sep 1;180(3):1025-35
    1. Proc Soc Exp Biol Med. 1994 Nov;207(2):197-205
    1. Gastroenterology. 1995 Jan;108(1):218-24
    1. J Exp Med. 1995 Mar 1;181(3):857-66
    1. J Biol Chem. 1995 Mar 10;270(10):5320-5
    1. J Exp Med. 1995 May 1;181(5):1743-54
    1. Infect Immun. 1995 Jul;63(7):2435-42
    1. Annu Rev Immunol. 1995;13:437-57
    1. J Lipid Res. 1995 Apr;36(4):736-44
    1. Immunopharmacology. 1995 Apr;29(3):187-205
    1. Gastroenterology. 1995 Sep;109(3):899-907
    1. Exp Mol Pathol. 1995 Feb;62(1):42-51
    1. Prog Clin Biol Res. 1995;392:297-304
    1. Prog Clin Biol Res. 1995;392:349-51
    1. Hepatology. 1995 Oct;22(4 Pt 1):1304-9
    1. Am J Physiol. 1996 Jun;270(6 Pt 1):G956-61
    1. J Biol Chem. 1996 Sep 20;271(38):23310-6
    1. Crit Rev Immunol. 1995;15(3-4):201-14
    1. Gastroenterology. 1997 Mar;112(3):943-51
    1. Nature. 1970 Aug 15;227(5259):680-5
    1. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4
    1. Alcohol Clin Exp Res. 1986 Jun;10(3):271-3
    1. J Hepatol. 1987 Feb;4(1):8-14

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅